Tim Watkins, CMO & Head of Development at Contineum Therapeutics, Inc. (CTNM), sold 10,833 shares at $16.02 ($174K) on 2026-06-30, disclosed to the SEC on 2026-07-01.
Scheduled sale ($174k) by CMO & Head of Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| CTNM | SELL | 2025-12-30 | $44K | — | Filing → |